Table of Content

Executive Summary

1 Product Definition
1.1 Inclusion and Exclusion Criteria

2 Market Scope
2.1 Key Questions Answered in the Report:

3 Research Methodology
3.1 Organ Transplant Diagnostics Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling

4 Overview
4.1 Current Market Scenario
4.1.1 For Researchers
4.1.2 For Diagnostics
4.2 Market Footprint
4.3 COVID-19 Impact on Market
4.3.1 Impact on Operations
4.3.2 COVID-19 Impact: Current Scenario of Market
4.3.3 Pre- and Post-COVID-19 Impact Assessment
4.3.3.1 Pre-COVID-19 Phase
4.3.3.2 Post-COVID-19 Phase

5 Europe
5.1 Europe
5.1.1 Europe Organ Transplant Test Volume, by Transplant Type
5.1.2 Market Sizing and Forecast
5.1.2.1 Europe Organ Transplant Diagnostics Market (by Country)
5.1.2.1.1 France
5.1.2.1.2 Spain
5.1.2.1.3 U.K.
5.1.2.1.4 Italy
5.1.2.1.5 Germany
5.1.2.1.6 Switzerland
5.1.2.1.7 Rest-of-Europe

6 Company Profiles
6.1 Overview
6.2 Manufacturers
6.2.1 BAG Group GmbH
6.2.1.1 Company Overview
6.2.1.2 Role of BAG Group GmbH in the Organ Transplant Diagnostics Market
6.2.1.3 Product Portfolio
6.2.1.4 Analyst Perception
6.2.2 bioM?rieux S.A.
6.2.2.1 Company Overview
6.2.2.2 Role of bioM?rieux S.A. in the Organ Transplant Diagnostics Market
6.2.2.3 Product Portfolio
6.2.2.4 Financials
6.2.2.5 Recent Developments
6.2.2.6 Analyst Perception
6.2.3 Eurobio Scientific (Genome Diagnostics B.V.)
6.2.3.1 Company Overview
6.2.3.2 Role of Eurobio Scientific (Genome Diagnostics B.V.) in the Organ Transplant Diagnostics Market
6.2.3.3 Product Portfolio
6.2.3.4 Analyst Perception
6.2.4 F. Hoffmann-La Roche Ltd.
6.2.4.1 Company Overview
6.2.4.2 Role of F. Hoffmann-La Roche Ltd. in the Organ Transplant Diagnostics Market
6.2.4.3 Product Portfolio
6.2.4.4 Financials
6.2.4.5 Recent Developments
6.2.4.6 Analyst Perception
6.2.5 Omixon Inc.
6.2.5.1 Company Overview
6.2.5.2 Role of Omixon Inc. in the Organ Transplant Diagnostics Market
6.2.5.3 Product Portfolio
6.2.5.4 Analyst Perception
6.2.6 QIAGEN N.V.
6.2.6.1 Company Overview
6.2.6.2 Role of QIAGEN N.V. in the Organ Transplant Diagnostics Market
6.2.6.3 Product Portfolio
6.2.6.4 Financials
6.2.6.5 Recent Developments
6.2.6.6 Analyst Perception
List of Figures
Figure 1: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 2: Organ Transplant Diagnostics Market, Impact Analysis
Figure 3: Organ Transplant Diagnostics Market (by Region), $Billion, 2022 and 2033
Figure 4: Organ Transplant Diagnostics Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 9: Organ Transplant Diagnostics Market Share and CAGR (by Region), 2022 and 2023-2033
Figure 10: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 11: Europe Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
Figure 12: France Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 13: Spain Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 14: U.K. Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 15: Italy Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 16: Germany Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 17: Switzerland Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 18: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 19: Total Number of Companies Profiled
Figure 20: Organ Transplant Diagnostics Market Overview, Key Companies
Figure 21: BAG Group GmbH: Overall Product Portfolio
Figure 22: bioM?rieux S.A.: Overall Product Portfolio
Figure 23: bioM?rieux S.A.: Overall Financials, $Million, 2019-2021
Figure 24: bioM?rieux S.A.: Net Revenue (by Region), $Million, 2019-2021
Figure 25: bioM?rieux S.A.: R&D Expenditure, $Million, 2019-2021
Figure 26: Eurobio Scientific (Genome Diagnostics B.V.): Overall Product Portfolio
Figure 27: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 28: F. Hoffmann-La Roche Ltd.: Overall Financials, $Billion, 2020-2022
Figure 29: F. Hoffmann-La Roche Ltd.: Net Revenue (by Business Segment), $Billion, 2020-2022
Figure 30: F. Hoffmann-La Roche Ltd.: Diagnostics Revenue (by Region), $Billion, 2020-2022
Figure 31: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Billion, 2020-2022
Figure 32: Omixon Inc.: Overall Product Portfolio
Figure 33: QIAGEN N.V.: Product Portfolio
Figure 34: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 35: QIAGEN N.V.: Net Revenue (by Business Segment), $Million, 2019-2021
Figure 36: QIAGEN N.V.: Net Revenue (by Region), $Million, 2019-2021
Figure 37: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
List of Tables
Table 1: Key Questions Answered in the Report
Table 2: Europe Organ Transplant Diagnostics Market, Impact Analysis
Table 3: Europe Organ Transplant Test Volume, by Transplant Type, 2021